Skip to main content

Table 4 Impact of donor statue on prevalence of TTIs by year

From: Trends and epidemiological analysis of hepatitis B virus, hepatitis C virus, human immunodeficiency virus, and human T-cell lymphotropic virus among Iranian blood donors: strategies for improving blood safety

Year Donation Number Number of confirmed positive samples
Prevalence /100000 donation (95%CI)
First time Regular
HBV HIV HCV HTLV HBV HIV HCV HTLV
2010 354,695 975,275 (240–310) 8 2.3 (1.5–3.4) 162 45.7 (41.6–50) 379,106.9 (100.6–1134) 56 15.8 (13.5–18.5) 0 17 4.8 (3.6–6.4) 47 13.3 (11.2–15.8)
2011 351,769 840,224.9 (215.8–234.4) 6 1.6 (0.9–2.6) 163 43.6 (39.6–47.8) 358 95.7 (89.8–101.9) 41 11.7 (9.7–14.2) 7 2 (1.3–3) 23 6.5 (5.1–8.3) 29 8.2 (6.6–10.2)
2012 393,317 723,184.4 (176.2–193) 5 1.3 (0.75–2.2) 147 37.5 (33.8–41.4) 263 67.1 (62.2–72.4) 17 4.3 (3.2–5.8) 2 0.5 (0.2–1.2) 7 1.8 (1.1–2.8) 23 5.8 (4.5–7.5)
2013 391,210 659,168.5 (160.6–176.7) 5 1.3 (0.75–2.2) 151 38.6 (34.9–42.6) 276 70.6 (65.5–76) 8 2 (1.3–3) 0 14 3.6 (2.6–5) 13 3.3 (2.3–4.6)
2014 405,133 630,153.1 (145.6–160.9) 5 1.2 (0.7–2) 117 28.4 (25.2–31.9) 292 71 (65.9–76.4) 42 10.4 (8.6–12.6) 3 0.7 (0.3–1.4) 16 3.9 (2.8–5.3) 19 4.7 (3.5–6.2)
2015 429,629 593,143.6 (136.3–156.2) 4 1 (0.54–1.8) 111 26.9 (23.8–30.3) 242 58.8 (54.2–63.7) 62 14.4 (12.7–17) 3 0.7 (0.3–1.4) 18 4.2 (3.1–5.7) 6 1.4 (0.8–2.3)
2016 419,665 471,112.2 (105.8–118.9) 10 2.4 (1.6–3.5) 111 26.4 (23.4–29.7) 239 57 (52.5–61.8) 19 4.5 (3.4–6) 2 0.5 (0.2–1.2) 11 2.6 (1.8–3.8) 13 3.1 (2.2–4.4)
2017 432,097 347 80.3 (74.9–86) 3 0.7 (0.3–1.4) 86 19.9 (17.3–22.9) 176 40.7 (36.9–44.8) 11 2.5 (1.7–3.7) 2 0.5 (0.2–1.2) 9 2.1 (1.4–3.2) 16 3.7 (2.7–5.1)
2018 445,345 298 66.9 (62–72.2) 4 0.9 (0.4–1.7) 61 13.7 (11.6–16.2) 137 30.8 (27.5–34.4) 12 2.7 (1.8–3.9) 4 0.9 (0.4–1.7) 4 0.9 (0.4–1.7) 9 2 (1.3–3)
Total 3,622,860 5536 152.8 (145.3–160.6) 50 1.4 (0.8–2.3) 1109 30.6 (27.3–34.2) 2362 65.2 (60.4–70.4) 268 7.4 (6–9.3) 23 0.6 (0.3–1.3) 119 3.3 (2.5–4.6) 175 4.8 (3.6–6.4)